EFPIA seeks "soft law approach" rather than wholesale revision of EU pricing legislation
This article was originally published in SRA
Executive Summary
Reopening the so-called "Transparency Directive" on the pricing and reimbursement of medicines must not compromise the confidentiality of pricing arrangements between pharmaceutical companies and payers, says Richard Bergström, director general of the European Federation of the Pharmaceutical Industries and Associations (EFPIA)1. Revealing details of such agreements would prevent differential pricing, he said. Mr Bergström's comments came as EFPIA responded to the European Commission's consultation on the possible review of the Transparency Directive (89/105/EEC).
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.